Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter study of fondaparinux versus low molecular weight heparin for VTE prophylaxis in cancer inpatients
ChiCTR2100049014Phase 4Not yet recruiting
- Sponsor
- Anhui Cancer Hospital
- Start
- Aug 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux and low molecular weight heparin calcium in venous thromboembolism (VTE) (2 arms), sponsored by Anhui Cancer Hospital. Primary endpoints: Thrombotic events during hospitalization and Massive hemorrhage during hospitalization. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
fondaparinuxlow molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2100049014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049014.